Field Medical announced it closed a $40 million Series A funding round to accelerate the development of its pulsed field ablation (PFA) technology.
The Cardiff-by-the-Sea, California-based company, led by Farapulse founder Dr. Steven Mickelsen, focuses on ventricular tachycardia (VT)—a different strategy from earlier PFA innovators targeting atrial fibrillation (AFib). The funding includes $20 million in new capital and $20 million from converted seed debt, with backing from strategics, venture firms, and family offices.
Proceeds will support two clinical studies, development of a commercial system, and preparations for the VERITAS VT trial. Field Medical’s FieldForce system, featuring a contact force focal PFA catheter, received FDA breakthrough designation in December 2024.
“This financing is a pivotal milestone as we redefine ablation therapy,” said Mickelsen.
Follow MEDWIRE.AI for the latest updates in cardiac innovation.
